Elevated plasma levels of N-terminal pro-brain natriuretic peptide in patients with chronic hepatitis C during interferon-based antiviral therapy
AIM： To investigate plasma levels of N-terminal probrain natriuretic peptide （NT-proBNP）, an established marker of cardiac function, in patients with chronic hepatitis C during interferon-based antiviral therapy.METHODS： Using a sandwich immunoassay, plasma levels of NT-proBNP were determined in 48...
Gespeichert in:
| Veröffentlicht in: | World journal of gastroenterology : WJG 2006-09, Vol.12 (36), p.5875-5877 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5877 |
|---|---|
| container_issue | 36 |
| container_start_page | 5875 |
| container_title | World journal of gastroenterology : WJG |
| container_volume | 12 |
| creator | Bojunga, Jorg Sarrazin, Christoph Hess, Georg Zeuzem, Stefan |
| description | AIM： To investigate plasma levels of N-terminal probrain natriuretic peptide （NT-proBNP）, an established marker of cardiac function, in patients with chronic hepatitis C during interferon-based antiviral therapy.METHODS： Using a sandwich immunoassay, plasma levels of NT-proBNP were determined in 48 patients with chronic hepatitis C at baseline, wk 24 and 48 during antiviral therapy and at wk 72 during follow-up.RESULTS： Plasma NT-proBNP concentrations were significantly increased （P 〈 0.05） at wk 24, 48 and 72 compared to the baseline values. NT-proBNP concentrations at baseline and wk 24 were closely correlated （r = 0.8; P 〈 0.001）. At wk 24, 7 （14.6%） patients had NT-proBNP concentrations above 200 ng/L compared to 1 （2%） patient at baseline （P = 0.059）. Six of these 7 patients had been treated with high-dose IFN-α induction therapy. In multiple regression analysis, NT-proBNP was not related to other clinical parameters, biochemical parameters of liver disease or virus load and response to therapy. CONCLUSION： Elevated levels of NT-proBNP during and after interferon-based antiviral therapy of chronic hepatitis C may indicate the presence of cardiac dysfunction, which may contribute to the clinical symptoms observed in patients during therapy. Plasma levels of NT-proBNP may be used as a diagnostic tool and for guiding therapy in patients during interferon- based antiviral therapy. |
| doi_str_mv | 10.3748/wjg.v12.i36.5875 |
| format | Article |
| fullrecord | <record><control><sourceid>wanfang_jour_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4100671</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>23044995</cqvip_id><wanfj_id>wjg200636019</wanfj_id><sourcerecordid>wjg200636019</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-2214d190b650f0874786eaf5a90d1b27a28f98facf079333afce18d40f6af38b3</originalsourceid><addsrcrecordid>eNpVkU2P0zAQhi0EYrsLd07IQlxT_JHE8QUJVcuCtILL7tmaJHbikjrBdlvtz-AfM1UrPk6WZ5555-Ml5A1na6nK5sNxO6wPXKy9rNdVo6pnZCUE14VoSvacrDhjqtBSqCtyndKWMSFlJV6SK64ww6p6RX7dTvYA2fZ0mSDtgOLXTonOjn4rso07H2CiS5yLNoIPNECOfh9t9h1d7JJ9bymGF8jehpzo0eeRdmOcAwKjPcWzT3RD-330YUAWRZ3FfNFCwrYQsj_4iE3yaCMsT6_ICwdTsq8v7w15_Hz7sPlS3H-_-7r5dF90ZcVygXuWPdesrSvmWKNK1dQWXAWa9bwVCkTjdOOgc0xpKSW4zvKmL5mrwcmmlTfk41l32bc723c4Pk5hluh3EJ_MDN78nwl-NMN8MCWetVYcBd6fBY4QHITBbOd9xGslg7YIZGTNuEaMnbEuzilF6_604MycXDzhBl006KI5uYglb_8d7W_BxTYE3l00xzkMP_GwpoXuh_OTNUKystS6kr8BW0appQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Elevated plasma levels of N-terminal pro-brain natriuretic peptide in patients with chronic hepatitis C during interferon-based antiviral therapy</title><source>MEDLINE</source><source>PMC (PubMed Central)</source><source>Alma/SFX Local Collection</source><creator>Bojunga, Jorg ; Sarrazin, Christoph ; Hess, Georg ; Zeuzem, Stefan</creator><creatorcontrib>Bojunga, Jorg ; Sarrazin, Christoph ; Hess, Georg ; Zeuzem, Stefan</creatorcontrib><description>AIM： To investigate plasma levels of N-terminal probrain natriuretic peptide （NT-proBNP）, an established marker of cardiac function, in patients with chronic hepatitis C during interferon-based antiviral therapy.METHODS： Using a sandwich immunoassay, plasma levels of NT-proBNP were determined in 48 patients with chronic hepatitis C at baseline, wk 24 and 48 during antiviral therapy and at wk 72 during follow-up.RESULTS： Plasma NT-proBNP concentrations were significantly increased （P 〈 0.05） at wk 24, 48 and 72 compared to the baseline values. NT-proBNP concentrations at baseline and wk 24 were closely correlated （r = 0.8; P 〈 0.001）. At wk 24, 7 （14.6%） patients had NT-proBNP concentrations above 200 ng/L compared to 1 （2%） patient at baseline （P = 0.059）. Six of these 7 patients had been treated with high-dose IFN-α induction therapy. In multiple regression analysis, NT-proBNP was not related to other clinical parameters, biochemical parameters of liver disease or virus load and response to therapy. CONCLUSION： Elevated levels of NT-proBNP during and after interferon-based antiviral therapy of chronic hepatitis C may indicate the presence of cardiac dysfunction, which may contribute to the clinical symptoms observed in patients during therapy. Plasma levels of NT-proBNP may be used as a diagnostic tool and for guiding therapy in patients during interferon- based antiviral therapy.</description><identifier>ISSN: 1007-9327</identifier><identifier>EISSN: 2219-2840</identifier><identifier>DOI: 10.3748/wjg.v12.i36.5875</identifier><identifier>PMID: 17007056</identifier><language>eng</language><publisher>United States: Internal Medicine Ⅱ, Saarland University Hospital, 66421 Homburg/Saar,Germany%Roche Diagnostics, 68305 Mannheim, Germany</publisher><subject>Adult ; Aged ; Antiviral Agents - therapeutic use ; Biomarkers - blood ; Female ; Heart Diseases - chemically induced ; Heart Diseases - diagnosis ; Hepatitis C, Chronic - blood ; Hepatitis C, Chronic - drug therapy ; Humans ; Interferon alpha-2 ; Interferon-alpha - adverse effects ; Interferon-alpha - therapeutic use ; Male ; Middle Aged ; Natriuretic Peptide, Brain - blood ; Peptide Fragments - blood ; Polyethylene Glycols - adverse effects ; Polyethylene Glycols - therapeutic use ; Rapid Communication ; Recombinant Proteins ; Regression Analysis ; 尿钠排泄 ; 慢性丙型肝炎 ; 抗病毒治疗 ; 等离子体</subject><ispartof>World journal of gastroenterology : WJG, 2006-09, Vol.12 (36), p.5875-5877</ispartof><rights>Copyright © Wanfang Data Co. Ltd. All Rights Reserved.</rights><rights>2006 Baishideng Publishing Group Co., Limited. All rights reserved. 2006</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-2214d190b650f0874786eaf5a90d1b27a28f98facf079333afce18d40f6af38b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/84123X/84123X.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100671/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100671/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17007056$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bojunga, Jorg</creatorcontrib><creatorcontrib>Sarrazin, Christoph</creatorcontrib><creatorcontrib>Hess, Georg</creatorcontrib><creatorcontrib>Zeuzem, Stefan</creatorcontrib><title>Elevated plasma levels of N-terminal pro-brain natriuretic peptide in patients with chronic hepatitis C during interferon-based antiviral therapy</title><title>World journal of gastroenterology : WJG</title><addtitle>World Journal of Gastroenterology</addtitle><description>AIM： To investigate plasma levels of N-terminal probrain natriuretic peptide （NT-proBNP）, an established marker of cardiac function, in patients with chronic hepatitis C during interferon-based antiviral therapy.METHODS： Using a sandwich immunoassay, plasma levels of NT-proBNP were determined in 48 patients with chronic hepatitis C at baseline, wk 24 and 48 during antiviral therapy and at wk 72 during follow-up.RESULTS： Plasma NT-proBNP concentrations were significantly increased （P 〈 0.05） at wk 24, 48 and 72 compared to the baseline values. NT-proBNP concentrations at baseline and wk 24 were closely correlated （r = 0.8; P 〈 0.001）. At wk 24, 7 （14.6%） patients had NT-proBNP concentrations above 200 ng/L compared to 1 （2%） patient at baseline （P = 0.059）. Six of these 7 patients had been treated with high-dose IFN-α induction therapy. In multiple regression analysis, NT-proBNP was not related to other clinical parameters, biochemical parameters of liver disease or virus load and response to therapy. CONCLUSION： Elevated levels of NT-proBNP during and after interferon-based antiviral therapy of chronic hepatitis C may indicate the presence of cardiac dysfunction, which may contribute to the clinical symptoms observed in patients during therapy. Plasma levels of NT-proBNP may be used as a diagnostic tool and for guiding therapy in patients during interferon- based antiviral therapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biomarkers - blood</subject><subject>Female</subject><subject>Heart Diseases - chemically induced</subject><subject>Heart Diseases - diagnosis</subject><subject>Hepatitis C, Chronic - blood</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Humans</subject><subject>Interferon alpha-2</subject><subject>Interferon-alpha - adverse effects</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Natriuretic Peptide, Brain - blood</subject><subject>Peptide Fragments - blood</subject><subject>Polyethylene Glycols - adverse effects</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Rapid Communication</subject><subject>Recombinant Proteins</subject><subject>Regression Analysis</subject><subject>尿钠排泄</subject><subject>慢性丙型肝炎</subject><subject>抗病毒治疗</subject><subject>等离子体</subject><issn>1007-9327</issn><issn>2219-2840</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkU2P0zAQhi0EYrsLd07IQlxT_JHE8QUJVcuCtILL7tmaJHbikjrBdlvtz-AfM1UrPk6WZ5555-Ml5A1na6nK5sNxO6wPXKy9rNdVo6pnZCUE14VoSvacrDhjqtBSqCtyndKWMSFlJV6SK64ww6p6RX7dTvYA2fZ0mSDtgOLXTonOjn4rso07H2CiS5yLNoIPNECOfh9t9h1d7JJ9bymGF8jehpzo0eeRdmOcAwKjPcWzT3RD-330YUAWRZ3FfNFCwrYQsj_4iE3yaCMsT6_ICwdTsq8v7w15_Hz7sPlS3H-_-7r5dF90ZcVygXuWPdesrSvmWKNK1dQWXAWa9bwVCkTjdOOgc0xpKSW4zvKmL5mrwcmmlTfk41l32bc723c4Pk5hluh3EJ_MDN78nwl-NMN8MCWetVYcBd6fBY4QHITBbOd9xGslg7YIZGTNuEaMnbEuzilF6_604MycXDzhBl006KI5uYglb_8d7W_BxTYE3l00xzkMP_GwpoXuh_OTNUKystS6kr8BW0appQ</recordid><startdate>20060928</startdate><enddate>20060928</enddate><creator>Bojunga, Jorg</creator><creator>Sarrazin, Christoph</creator><creator>Hess, Georg</creator><creator>Zeuzem, Stefan</creator><general>Internal Medicine Ⅱ, Saarland University Hospital, 66421 Homburg/Saar,Germany%Roche Diagnostics, 68305 Mannheim, Germany</general><general>Baishideng Publishing Group Co., Limited</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>2B.</scope><scope>4A8</scope><scope>92I</scope><scope>93N</scope><scope>PSX</scope><scope>TCJ</scope><scope>5PM</scope></search><sort><creationdate>20060928</creationdate><title>Elevated plasma levels of N-terminal pro-brain natriuretic peptide in patients with chronic hepatitis C during interferon-based antiviral therapy</title><author>Bojunga, Jorg ; Sarrazin, Christoph ; Hess, Georg ; Zeuzem, Stefan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-2214d190b650f0874786eaf5a90d1b27a28f98facf079333afce18d40f6af38b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biomarkers - blood</topic><topic>Female</topic><topic>Heart Diseases - chemically induced</topic><topic>Heart Diseases - diagnosis</topic><topic>Hepatitis C, Chronic - blood</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Humans</topic><topic>Interferon alpha-2</topic><topic>Interferon-alpha - adverse effects</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Natriuretic Peptide, Brain - blood</topic><topic>Peptide Fragments - blood</topic><topic>Polyethylene Glycols - adverse effects</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Rapid Communication</topic><topic>Recombinant Proteins</topic><topic>Regression Analysis</topic><topic>尿钠排泄</topic><topic>慢性丙型肝炎</topic><topic>抗病毒治疗</topic><topic>等离子体</topic><toplevel>online_resources</toplevel><creatorcontrib>Bojunga, Jorg</creatorcontrib><creatorcontrib>Sarrazin, Christoph</creatorcontrib><creatorcontrib>Hess, Georg</creatorcontrib><creatorcontrib>Zeuzem, Stefan</creatorcontrib><collection>维普_期刊</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Wanfang Data Journals - Hong Kong</collection><collection>WANFANG Data Centre</collection><collection>Wanfang Data Journals</collection><collection>万方数据期刊 - 香港版</collection><collection>China Online Journals (COJ)</collection><collection>China Online Journals (COJ)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of gastroenterology : WJG</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bojunga, Jorg</au><au>Sarrazin, Christoph</au><au>Hess, Georg</au><au>Zeuzem, Stefan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elevated plasma levels of N-terminal pro-brain natriuretic peptide in patients with chronic hepatitis C during interferon-based antiviral therapy</atitle><jtitle>World journal of gastroenterology : WJG</jtitle><addtitle>World Journal of Gastroenterology</addtitle><date>2006-09-28</date><risdate>2006</risdate><volume>12</volume><issue>36</issue><spage>5875</spage><epage>5877</epage><pages>5875-5877</pages><issn>1007-9327</issn><eissn>2219-2840</eissn><abstract>AIM： To investigate plasma levels of N-terminal probrain natriuretic peptide （NT-proBNP）, an established marker of cardiac function, in patients with chronic hepatitis C during interferon-based antiviral therapy.METHODS： Using a sandwich immunoassay, plasma levels of NT-proBNP were determined in 48 patients with chronic hepatitis C at baseline, wk 24 and 48 during antiviral therapy and at wk 72 during follow-up.RESULTS： Plasma NT-proBNP concentrations were significantly increased （P 〈 0.05） at wk 24, 48 and 72 compared to the baseline values. NT-proBNP concentrations at baseline and wk 24 were closely correlated （r = 0.8; P 〈 0.001）. At wk 24, 7 （14.6%） patients had NT-proBNP concentrations above 200 ng/L compared to 1 （2%） patient at baseline （P = 0.059）. Six of these 7 patients had been treated with high-dose IFN-α induction therapy. In multiple regression analysis, NT-proBNP was not related to other clinical parameters, biochemical parameters of liver disease or virus load and response to therapy. CONCLUSION： Elevated levels of NT-proBNP during and after interferon-based antiviral therapy of chronic hepatitis C may indicate the presence of cardiac dysfunction, which may contribute to the clinical symptoms observed in patients during therapy. Plasma levels of NT-proBNP may be used as a diagnostic tool and for guiding therapy in patients during interferon- based antiviral therapy.</abstract><cop>United States</cop><pub>Internal Medicine Ⅱ, Saarland University Hospital, 66421 Homburg/Saar,Germany%Roche Diagnostics, 68305 Mannheim, Germany</pub><pmid>17007056</pmid><doi>10.3748/wjg.v12.i36.5875</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1007-9327 |
| ispartof | World journal of gastroenterology : WJG, 2006-09, Vol.12 (36), p.5875-5877 |
| issn | 1007-9327 2219-2840 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4100671 |
| source | MEDLINE; PMC (PubMed Central); Alma/SFX Local Collection |
| subjects | Adult Aged Antiviral Agents - therapeutic use Biomarkers - blood Female Heart Diseases - chemically induced Heart Diseases - diagnosis Hepatitis C, Chronic - blood Hepatitis C, Chronic - drug therapy Humans Interferon alpha-2 Interferon-alpha - adverse effects Interferon-alpha - therapeutic use Male Middle Aged Natriuretic Peptide, Brain - blood Peptide Fragments - blood Polyethylene Glycols - adverse effects Polyethylene Glycols - therapeutic use Rapid Communication Recombinant Proteins Regression Analysis 尿钠排泄 慢性丙型肝炎 抗病毒治疗 等离子体 |
| title | Elevated plasma levels of N-terminal pro-brain natriuretic peptide in patients with chronic hepatitis C during interferon-based antiviral therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T03%3A07%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wanfang_jour_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elevated%20plasma%20levels%20of%20N-terminal%20pro-brain%20natriuretic%20peptide%20in%20patients%20with%20chronic%20hepatitis%20C%20during%20interferon-based%20antiviral%20therapy&rft.jtitle=World%20journal%20of%20gastroenterology%20:%20WJG&rft.au=Bojunga,%20Jorg&rft.date=2006-09-28&rft.volume=12&rft.issue=36&rft.spage=5875&rft.epage=5877&rft.pages=5875-5877&rft.issn=1007-9327&rft.eissn=2219-2840&rft_id=info:doi/10.3748/wjg.v12.i36.5875&rft_dat=%3Cwanfang_jour_pubme%3Ewjg200636019%3C/wanfang_jour_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17007056&rft_cqvip_id=23044995&rft_wanfj_id=wjg200636019&rfr_iscdi=true |